Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

4.44
+0.470011.84%
Post-market: 4.700.2565+5.78%19:55 EDT
Volume:191.11K
Turnover:814.81K
Market Cap:66.70M
PE:-0.91
High:4.47
Open:3.94
Low:3.94
Close:3.97
Loading ...

BRIEF-Jasper Therapeutics Inc Files For Common Stock Offering Of Up To $100 Million - SEC Filing

Reuters
·
27 Mar

Jasper Therapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
20 Mar

Jasper Therapeutics Signs New Sales Agreement with Jefferies

TIPRANKS
·
20 Mar

BRIEF-Jasper Therapeutics terminates Cantor sales agreement

Reuters
·
20 Mar

Jasper Therapeutics files $300M mixed securities shelf

TIPRANKS
·
20 Mar

Jasper Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Mar

Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics

TIPRANKS
·
12 Mar

Jasper Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
03 Mar

Analysts’ Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), Jasper Therapeutics (JSPR)

TIPRANKS
·
03 Mar

Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments

TIPRANKS
·
03 Mar

Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study

TIPRANKS
·
02 Mar

RBC Capital Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)

TIPRANKS
·
02 Mar

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

GlobeNewswire
·
02 Mar

Buy Recommendation for Jasper Therapeutics: Promising Developments in Briquilimab’s Phase 2b Program

TIPRANKS
·
01 Mar

Jasper Therapeutics Inc expected to post a loss of $1.26 a share - Earnings Preview

Reuters
·
28 Feb

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

GlobeNewswire
·
28 Feb

Jasper Therapeutics: Strategic Advancements and Promising Clinical Efficacy Drive Buy Rating

TIPRANKS
·
28 Feb

Promising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab

TIPRANKS
·
28 Feb

Jasper Therapeutics Q4 EPS $(1.62) Misses $(1.23) Estimate

Benzinga
·
27 Feb

Jasper Therapeutics Q4 Income From Operation USD -25.285 Million

THOMSON REUTERS
·
27 Feb